TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05375799

Intervention type: OTHER
Intervention: Clinical Observation
Description: This is an observational study, so there are no interventions. Data will be recruited from adult patients diagnosed with COVID-19, described in medical records, by laboratory detection of SARS-CoV-2 RNA, who used the Assisted Breathing Helmet - ELMO.~All the following predictor variables will be collected: demographic and anthropometric data; clinical characteristics of patients (comorbidities, date of onset of symptoms and initial symptoms, hospital admission, laboratory tests, chest X-ray tests, need for intubation or ICU admission); start date of ELMO use, blood gas analysis before and after the first application of ELMO and data related to its use (number of applications, number of days of therapy, total time of therapy, as well as reasons for the interruption and adverse effects ).
Study: NCT04711577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Track clinician-determined symptoms
Description: Participants will track clinician-determined symptoms

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Track clinician-determined and self-determined symptoms
Description: Participants will track clinician-determined symptoms and a self-determined symptom
Study: NCT04967703

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A
Description: Patients received ultrasound therapy protocol with the following parameters (1 MHz frequency, intensity of 1.5 W/cm2 and use of continuous mode of ultrasound for 5 minutes), in addition to a conventional physiotherapy program consisting of calf muscles stretching, plantar fascia stretch, strengthening exercises and manual massage for 3 sessions per week, for 4 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group B
Description: Patients received radial shock wave therapy protocol with the following parameters (1) the energy level was 0.12 mJ/mm2 equivalent to 2.5 bar intensity, (2) the number of shoots was 2000, (3) the frequency was 8 Hz, in addition to the same conventional physiotherapy program given for group A

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group C
Description: Patients received both ultrasound and radial shock wave therapy, in addition to the same conventional physiotherapy program given for group A
Study: NCT05849753

Intervention type: DEVICE
Intervention: Advanced artificial pancreas closed-loop technology
Description: Study is an observational capture of data in patients that qualify, before and after the use of any FDA-approved closed-loop system of Subject's/Family's choosing that uses a CGM that does not require fingerprick calibrations. Devices prescribed available through their insurance (including Medicaid).
Study: NCT06546800

Intervention type: BIOLOGICAL
Intervention: RSVpreF vaccine
Description: Injection in the muscle, 1 dose 0.5mL
Study: NCT04538053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral cefalexin only
Description: High-dose oral cefalexin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV cefazolin or IV flucloxacillin followed by oral cefalexin
Description: Standard therapy of IV cefazolin or IV flucloxacillin followed by high dose oral cefalexin
Study: NCT05200416

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heylo
Description: Heylo is used in combination with the ostomy baseplate usually used by the subjects. It will detect and notify the subject of the occurrence of output leakage under an ostomy baseplate.
Study: NCT05831072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-cognitive oriented group program
Description: Mindfulness-cognitive oriented group program is a 4-week program based on the theory of mindfulness-based cognitive therapy (MBCT). The main elements of MBCT such as mindfulness breathing, raisin meditation for mindful eating, body scan and mindfulness walking are included. In addition to the weekly intervention, participants are also required to do the mindfulness practice at home.
Study: NCT06440759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oXiris filter
Description: Continuous Renal Replacement Therapy with the adsorption membrane filter Oxiris.~The specific septic biomarkers such as interleukin 6(IL-6), procalcitonin (PCT), C-reactive protein (CRP) along with other routine blood investigation results taken at the beginning of therapy and 24 hours after the treatment will be compared.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: M100 filter
Description: Continuous Renal Replacement Therapy with the adsorption membrane filter M100. The specific septic biomarkers such as interleukin 6(IL-6), procalcitonin (PCT), C-reactive protein (CRP) along with other routine blood investigation results taken at the beginning of therapy and 24 hours after the treatment will be compared.
Study: NCT04449809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: 3x per week group monitored group exercise sessions
Study: NCT04808895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: administration of one tablet daily for 15 days. On the first day a loading dose of 300 mg will be administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administration of one tablet daily for 15 days. On the first day 3 tablets will be administered
Study: NCT05200416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heylo
Description: Heylo is used in combination with the ostomy baseplate usually used by the subjects. It will detect and notify the subject of the occurrence of output leakage under an ostomy baseplate.
Study: NCT05200416

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care is the ostomy products (baseplate and bag) that the subject normally uses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care is the ostomy products (baseplate and bag) that the subject normally uses
Study: NCT06366750

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: barzolvolimab
Description: subcutaneous administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: barzolvolimab
Description: subcutaneous administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: subcutaneous administration
Study: NCT05239793

Intervention type: DRUG
Group type: OTHER
Intervention: NJOY e-cigarette
Description: NJOY e-cigarette with Virginia Tobacco flavored 5% nicotine pods
Study: NCT05921266

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Urolithin A
Description: Participants in the intervention group will receive 500 mg of urolithin A twice daily for 4 weeks (1,000 mg daily in total). The supplement will be administered in the form of softgels (4 softgels daily).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the control group will receive 0 mg of urolithin A twice daily for 4 weeks. The placebo will be administered in the form of inactive capsules (4 capsules daily).
Study: NCT04426214

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: We will apply tDCS in combination with cognitive training. All participants receive cognitive training, and will be randomized to receive either active or sham tDCS

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: cognitive training on computer

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Training
Description: cognitive training on computer
Study: NCT06254872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentors
Description: Peer mentors provide daily guidance and encouragement to mentees via smartphone app based on training.
Study: NCT04902443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered as an oral planned starting dose of 3 mg daily (dose escalation) or at an MTD of 4 mg (dose expansion). Pomalidomide will be given from day 1 to day 21 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered as an oral planned starting dose of 3 mg daily (dose escalation) or at an MTD of 4 mg (dose expansion). Pomalidomide will be given from day 1 to day 21 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered as an oral planned starting dose of 3 mg daily (dose escalation) or at an MTD of 4 mg (dose expansion). Pomalidomide will be given from day 1 to day 21 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered IV at a dose of 480 mg at day one of each cycle, except for cycle one when it will be administered on day 8. One cycle equals 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered IV at a dose of 480 mg at day one of each cycle, except for cycle one when it will be administered on day 8. One cycle equals 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered IV at a dose of 480 mg at day one of each cycle, except for cycle one when it will be administered on day 8. One cycle equals 28 days
Study: NCT05092022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evalyn Self-Sampling Brush
Description: A self-sampling brush to collect cervical cells for screening purposes.
Study: NCT05578976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous (IV) Injection
Study: NCT04607616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qualitative analysis
Description: Interpretative Phenomenological Analysis. Parents' semi structured interview about the Interactive Guidance experience. Qualitative analysis of transcripts (recurrent themes, meta themes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qualitative analysis
Description: Interpretative Phenomenological Analysis. Parents' semi structured interview about the Interactive Guidance experience. Qualitative analysis of transcripts (recurrent themes, meta themes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qualitative analysis
Description: Interpretative Phenomenological Analysis. Parents' semi structured interview about the Interactive Guidance experience. Qualitative analysis of transcripts (recurrent themes, meta themes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qualitative analysis
Description: Interpretative Phenomenological Analysis. Parents' semi structured interview about the Interactive Guidance experience. Qualitative analysis of transcripts (recurrent themes, meta themes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qualitative analysis
Description: Interpretative Phenomenological Analysis. Parents' semi structured interview about the Interactive Guidance experience. Qualitative analysis of transcripts (recurrent themes, meta themes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qualitative analysis
Description: Interpretative Phenomenological Analysis. Parents' semi structured interview about the Interactive Guidance experience. Qualitative analysis of transcripts (recurrent themes, meta themes).
Study: NCT05125432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture group
Description: Acupuncture group Patients with breast cancer who experienced AIA were assessed by the Brief Pain Inventory (BPI)scale and McMasters College Osteoarthritis Index Score (WOMAC). Patients who met the criteria for inclusion would receive regular acupuncture treatment. The location of acupuncture is based on the principles of acupuncture treatment in Traditional Chinese medicine. Patients with high scores and obvious pain received standardized acupuncture treatment, and standard acupuncture points and most painful joint (up to 3) specific point. Meanwhile, blood samples of patients were collected, and SNP related to AIA was screened through SNP typing technology.
Study: NCT05466253

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fixed Orthodontic treatment
Description: All the patients will receive the indicated periodontal surgical treatment. and the patients will then be randomly divided into two groups - test group and control group Orthodontic treatment will be started in the test group (EARLY)10 days after periodontal surgery whereas the control group will receive orthodontic intervention (DELAYED) 3 months after periodontal surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fixed Orthodontic treatment
Description: All the patients will receive the indicated periodontal surgical treatment. and the patients will then be randomly divided into two groups - test group and control group Orthodontic treatment will be started in the test group (EARLY)10 days after periodontal surgery whereas the control group will receive orthodontic intervention (DELAYED) 3 months after periodontal surgery.
Study: NCT06265805

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive rehabilitation therapy
Description: Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation therapy
Description: Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
Study: NCT05159765

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Single vision contact lenses
Description: Wearing contact lenses during waking hours may alter the progression of myopia
Study: NCT05535088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Virtual reality consists for about a minute and a half 6 times per session. During the first and the second session, subjects will experiment virtual reality while sited. Moreover, during the third and the fourth session subjects will be standing with a side by side stand. During the last two experimental sessions subjetcts will be standing with a semi tandem stand.
Study: NCT05578976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous (IV) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV Infusion
Study: NCT06163638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GRANDPACT Project
Description: To investigate whether grandparents and grandchildren are more co-physically active, have a better cognitive and physical function, psychosocial well-being, quality of the family relationship due to the intervention, we compare the intervention phase (B) with a pre phase (A), a in between period (A) and another intervention period (B)
Study: NCT05600322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hexaminolevulinate Hydrochloride
Description: Enrolled patients will be instilled with 50 mL hexaminolevulinate hydrochloride as intravesical solution (Hexvix) in the bladder for one hour at Visit 2. After bladder evacuation, the cystoscopic examinations will be performed in both white and blue light.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Richard Wolf Photodynamic Diagnostic Equipment (PDD) system
Description: Cystoscopy in White and Blue light will be done using the Richard Wolf PDD system.
Study: NCT06146374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for SLV213
Description: Microcrystalline cellulose in a size 1 orange hard gelatin capsule.
Study: NCT05159765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifocal contact lenses
Description: Wearing contact lenses during waking hours may alter the progression of myopia
Study: NCT05742750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab and Apatinib Plus GP
Description: Patients received apatinib orally at 250 mg once a day irrespective of the patient weight.~Camrelizumab 200 mg was administered intravenously over 30 minutes every 3 weeks.~GP chemotherapy: Gemcitabine/Cisplatin (gemcitabine 1000mg/m2 + cisplatin 25mg/m2) will be administered on D1/D8 in every three weeks cycle and up to 8 cycles.~All patients continued combination treatment until disease progression, unacceptable toxicity, or discontinuation for any reason.
Study: NCT06146374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for SLV213
Description: Microcrystalline cellulose in a size 1 orange hard gelatin capsule.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for SLV213
Description: Microcrystalline cellulose in a size 1 orange hard gelatin capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV213
Description: SLV213 drug substance (K777) is 4-methylpiperazine-1-carboxylic acid, a vinyl sulfone cysteine protease inhibitor for the treatment of subjects infected with SARS-CoV-2. SLV213 is a white powder substance without excipients or stabilizer that will be packed into gelatin capsules which has been demonstrated to exhibit broad inhibitory properties against host cathepsins (e.g., Cathepsin L).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV213
Description: SLV213 drug substance (K777) is 4-methylpiperazine-1-carboxylic acid, a vinyl sulfone cysteine protease inhibitor for the treatment of subjects infected with SARS-CoV-2. SLV213 is a white powder substance without excipients or stabilizer that will be packed into gelatin capsules which has been demonstrated to exhibit broad inhibitory properties against host cathepsins (e.g., Cathepsin L).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV213
Description: SLV213 drug substance (K777) is 4-methylpiperazine-1-carboxylic acid, a vinyl sulfone cysteine protease inhibitor for the treatment of subjects infected with SARS-CoV-2. SLV213 is a white powder substance without excipients or stabilizer that will be packed into gelatin capsules which has been demonstrated to exhibit broad inhibitory properties against host cathepsins (e.g., Cathepsin L).
Study: NCT05234983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifeFirst SWASTH brief advice intervention
Description: This intervention will support tobacco cessation among patients of high-reach, low-resource community healthcare settings in Mumbai (TB clinics, dental practices, and NGO-run health centers). The intervention will also use technology to build the capacity of practitioners in these settings to use evidence-based practices in their work and allow them to network and exchange best practices with one another.
Study: NCT05143931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home food environment and grocery delivery (AVOID)
Description: Participants (Arms 2 \& 4) will receive 6 months of coaching (Zoom and/or email/text) to modify their home food environment and alter cues to promote healthy food choices

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home food environment and grocery delivery (AVOID)
Description: Participants (Arms 2 \& 4) will receive 6 months of coaching (Zoom and/or email/text) to modify their home food environment and alter cues to promote healthy food choices

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhibitory control training (RESIST)
Description: Participants assigned to RESIST (Arms 3 \& 4) will receive 6 months of coaching (Zoom and/or email/text) and gamified inhibitory control training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhibitory control training (RESIST)
Description: Participants assigned to RESIST (Arms 3 \& 4) will receive 6 months of coaching (Zoom and/or email/text) and gamified inhibitory control training.
Study: NCT05578976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral; Tablet
Study: NCT06011070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gambling Personalised Feedback
Description: The intervention is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in gambling
Study: NCT05539053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N Acetylcysteine A
Description: paclitaxel + N-Acetylcysteine orally short course